Kalaris Therapeutics Inc

NASDAQ: KLRS · Healthcare · Biotechnology

PublicHQ Cambridge, MA · MiddlesexCIK 0001754068Reports USD

#1004 of 1,394 Healthcare companies by revenue

EA Score

30D

FH 34DQ 21GM —SS 41

v0.1 · 55/100 weight · provisional

↑ balance-sheet leverage, market scale · ↓ disclosure history, Piotroski F

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$43.4M

Employees

Market cap

$88.8M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$165.0k$165.0k2020

Net income-$43.4M-$43.4M2025

Operating income-$46.2M-$46.2M2025

Total assets$121.7M$121.7M2025

Liabilities$42.9M$42.9M2025

Equity$78.8M$78.8M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Kalaris Therapeutics Inc booked $165.0k in FY2020 revenue — among the slowest-growing Healthcare companies we track, at a -26326.1% net margin.

Peers · Healthcare

Seer, Inc.49D Lixte Biotechnology Holdings, Inc.41D Neonc Technologies Holdings, Inc.10D MAIA Biotechnology, Inc.34D

Neighbors

Middlesex →

GE Vernova Inc.$38.1B63C Thermo Fisher Scientific Inc.$44.6B86A Analog Devices, Inc.$11.0B87A The TJX Companies, Inc.$60.4B85A Boston Scientific Corporation$20.1B88A Alnylam Pharmaceuticals, Inc.$3.7B79B+

Key facts

CEOAndrew Oxtoby

SectorHealthcare

IndustryBiotechnology

HeadquartersCambridge, MA

ExchangeNASDAQ: KLRS

Employees14

IPO date2020-07-30

Latest filings

8-K2026-07-06 8-K2026-06-04 10-Q2026-05-12 8-K2026-05-12 DEF 14A2026-04-24 8-K2026-04-10 8-K2026-03-17 10-K2026-03-17

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.